Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients
Cancer Immunology, Immunotherapy · 05.07.2024 · 73 (9)
DOI: 10.1007/s00262-024-03750-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 05.07.2024. Verfasst von A Gawaz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. andrea.gawaz@med.uni-tuebingen.de. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma, Antibodies, Monoclonal, Humanized, Nivolumab. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Tübingen.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICI) applied in patients with melanoma in an adjuvant setting have proven safety and efficacy in several studies, but data on elderly patients aged 75 years or more is scarce. Aim of this study was to investigate efficacy and safety of adjuvant ICI in patients aged ≥ 75 years compared to patients < 75 years in a real-world setting.
Methods
We retrospectively analyzed clinical data, including occurrence of immune-related adverse events (irAE) and outcome of 456 patients that had been treated with adjuvant ICI between January 1st, 2018 and December 20th, 2022. We then compared patients aged ≥ 75 years ( n = 117) to patients < 75 years ( n = 339) in terms of safety and disease-free survival (DFS). Results and conclusion ICI were well tolerated in both groups, with no significant difference observed in the overall occurrence of irAE. However, within the elderly subgroup, there was a significantly higher proportion of skin or nephrological toxicity and colitis/diarrhea compared to the other group. In terms of efficacy, a significantly shorter DFS in patients aged ≥ 75 years was observed. Adjuvant ICI in patients ≥ 75 years was less effective and furthermore associated with an increased risk for skin, renal or bowel toxicity. Therefore, in elderly patients, adjuvant ICI should be used with precaution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. andrea.gawaz@med.uni-tuebingen.de.
- Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
Förderung
- Universitätsklinikum Tübingen
Zitieren
APA
Gawaz, A., Wolff, I., Nanz, L., Flatz, L., & Forschner, A. (2024). Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer Immunology, Immunotherapy, 73(9). https://doi.org/10.1007/s00262-024-03750-1
Vancouver
Gawaz A, Wolff I, Nanz L, Flatz L, Forschner A. Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer Immunology, Immunotherapy. 2024;73(9). doi:10.1007/s00262-024-03750-1
BibTeX
@article{Gawaz2024,
author = {Gawaz, A and Wolff, I and Nanz, L and Flatz, L and Forschner, A},
title = {Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {9},
doi = {10.1007/s00262-024-03750-1}
}
EUVIMED